Table 1 Characteristics of study subjects (n = 93) stratified by N-BP exposure and the occurrence of bisphosphonate-associated osteonecrosis of the jaw (ONJ)
Group | N | Mean age (years ± SD) | Median length of time on N-BP therapy (days, range) | Characteristics and type of N-BP therapy |
|---|---|---|---|---|
N-BP treatment naïve controls | 26 | 66.4 ± 10.0 | NA | 18 with osteoporosis (mean age 72.1 ± 6) |
8 Postmenopausal women without osteoporosis (mean age 53.6 ± 2) | ||||
Oral N-BP | 30 | 74.1 ± 5.7 | 90 (1,764) | 90% On oral alendronate (70 mg/week); 10% on oral ibandronate (150 mg/months) |
Intravenous N-BP | 31 | 73.2 ± 5.5 | 813 (1,982) | All on intravenous ibandronate (3 mg/months) |
ONJ | 6 | 61.3 ± 12.5 | 1,113 (1,282) | 1 Woman (85 yrs) was being treated with 5 mg/year intravenous zoledronate (had received 2 shots) for osteoporosis, previously had a blood malignancy and was on prednisone |
1 Woman on systemic corticosteroids and mycophenolate mofetil on oral aledronate (70 mg/week) for 3.5 years | ||||
1 Woman on interferon therapy for hepatitis B & C on oral aledronate (70 mg/week) for 5 years | ||||
3 Women who had been treated for metastatic breast cancer; all on 4 mg/months intravenous zoledronate (from 1.4 to 2.8 years) |